News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
743,719 Results
Type
Article (43994)
Company Profile (468)
Press Release (699239)
Multimedia
Podcasts (136)
Webinars (23)
Section
Business (209430)
Career Advice (2044)
Deals (36185)
Drug Delivery (134)
Drug Development (84061)
Employer Resources (174)
FDA (16761)
Job Trends (15211)
News (354458)
Policy (33303)
Tag
2027 BioCapital Elite (1)
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (4)
Academia (2677)
Accelerated approval (46)
Adcomms (29)
Allergies (166)
Alliances (51113)
ALS (204)
Alzheimer's disease (1815)
Antibody-drug conjugate (ADC) (406)
Approvals (17061)
Artificial intelligence (642)
Autoimmune disease (238)
Automation (51)
Bankruptcy (374)
Best Places to Work (11840)
BIOSECURE Act (20)
Biosimilars (209)
Biotechnology (330)
Bladder cancer (182)
Brain cancer (69)
Breast cancer (708)
Cancer (5555)
Cardiovascular disease (472)
Career advice (1733)
Career pathing (42)
CAR-T (317)
CDC (56)
Celiac Disease (2)
Cell therapy (851)
Cervical cancer (43)
Clinical research (72223)
Collaboration (2049)
Company closure (4)
Compensation (1319)
Complete response letters (85)
COVID-19 (2792)
CRISPR (108)
C-suite (1051)
Cystic fibrosis (158)
Data (7269)
Decentralized trials (3)
Denatured (43)
Depression (165)
Dermatology (66)
Diabetes (557)
Diagnostics (6905)
Digital health (53)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (320)
Drug pricing (207)
Drug shortages (32)
Duchenne muscular dystrophy (285)
Earnings (92409)
Editorial (65)
Employer branding (21)
Employer resources (153)
Events (122298)
Executive appointments (1075)
FDA (20289)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (14)
Frontotemporal dementia (33)
Funding (1709)
Gene editing (232)
Generative AI (56)
Gene therapy (715)
GLP-1 (1074)
Government (4807)
Grass and pollen (6)
Guidances (401)
Healthcare (19288)
HIV (76)
Huntington's disease (54)
IgA nephropathy (97)
Immunology and inflammation (303)
Immuno-oncology (91)
Indications (164)
Infectious disease (3119)
Inflammatory bowel disease (213)
Inflation Reduction Act (17)
Influenza (133)
Intellectual property (281)
Interviews (316)
IPO (16941)
IRA (53)
Job creations (3717)
Job search strategy (1441)
JPM (67)
Kidney cancer (18)
Labor market (93)
Layoffs (590)
Leadership (37)
Legal (8030)
Liver cancer (100)
Longevity (28)
Lung cancer (739)
Lymphoma (416)
Machine learning (55)
Management (59)
Manufacturing (965)
MASH (186)
Medical device (14022)
Medtech (14102)
Mergers & acquisitions (20419)
Metabolic disorders (1483)
mRNA (201)
Multiple sclerosis (181)
NASH (20)
Neurodegenerative disease (412)
Neuropsychiatric disorders (106)
Neuroscience (3298)
Neurotech (1)
NextGen: Class of 2026 (6773)
Non-profit (4597)
Now hiring (74)
Obesity (712)
Opinion (303)
Ovarian cancer (198)
Pain (240)
Pancreatic cancer (269)
Parkinson's disease (361)
Partnered (34)
Patents (567)
Patient recruitment (628)
Peanut (61)
People (60765)
Pharmaceutical (80)
Pharmacy benefit managers (33)
Phase 1 (22706)
Phase 2 (31860)
Phase 3 (23533)
Pipeline (7447)
Policy (322)
Postmarket research (2603)
Preclinical (9702)
Press Release (67)
Prostate cancer (287)
Psychedelics (57)
Radiopharmaceuticals (328)
Rare diseases (1071)
Real estate (6070)
Recruiting (71)
Regulatory (25581)
Reports (54)
Research institute (2505)
Resumes & cover letters (355)
Rett syndrome (33)
RNA editing (22)
RSV (86)
Schizophrenia (174)
Series A (285)
Series B (217)
Service/supplier (11)
Sickle cell disease (114)
Special edition (27)
Spinal muscular atrophy (169)
Sponsored (46)
Startups (3819)
State (2)
Stomach cancer (19)
Supply chain (129)
Tariffs (88)
The Weekly (90)
Vaccines (1096)
Venture capital (106)
Weight loss (461)
Women's health (116)
Worklife (20)
Date
Today (144)
Last 7 days (543)
Last 30 days (2586)
Last 365 days (30897)
2026 (8951)
2025 (31063)
2024 (36290)
2023 (41014)
2022 (52277)
2021 (56763)
2020 (54920)
2019 (47416)
2018 (35696)
2017 (33023)
2016 (32346)
2015 (38396)
2014 (32185)
2013 (27109)
2012 (29220)
2011 (29863)
2010 (27992)
Location
Africa (756)
Alabama (97)
Alaska (7)
Arizona (341)
Arkansas (16)
Asia (40988)
Australia (6817)
California (12627)
Canada (3582)
China (1294)
Colorado (542)
Connecticut (551)
Delaware (375)
Europe (90057)
Florida (1888)
Georgia (404)
Hawaii (3)
Idaho (62)
Illinois (1002)
India (84)
Indiana (576)
Iowa (24)
Japan (508)
Kansas (133)
Kentucky (48)
Louisiana (39)
Maine (75)
Maryland (1522)
Massachusetts (9157)
Michigan (351)
Minnesota (697)
Mississippi (6)
Missouri (142)
Montana (35)
Nebraska (29)
Nevada (137)
New Hampshire (87)
New Jersey (3371)
New Mexico (31)
New York (3317)
North Carolina (1666)
North Dakota (9)
Northern California (6234)
Ohio (376)
Oklahoma (23)
Oregon (44)
Pennsylvania (2540)
Puerto Rico (28)
Rhode Island (51)
South America (1126)
South Carolina (81)
South Dakota (2)
Southern California (4949)
Tennessee (200)
Texas (1988)
United States (44928)
Utah (379)
Vermont (1)
Virginia (302)
Washington D.C. (81)
Washington State (1036)
West Virginia (4)
Wisconsin (125)
Wyoming (2)
743,719 Results for "mabwell therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Mabwell Announces First Patient Dosed in Phase II Trial of Anti-IL-11 Antibody for Pathological Scarring
December 30, 2025
·
4 min read
Press Releases
Mabwell Announces First-Patient Dosed in Clinical Trial of Novel CDH17-Targeting ADC 7MW4911 in the U.S.
January 23, 2026
·
4 min read
Press Releases
Mabwell Announces First-Patient Dosing for Novel CDH17-Targeting ADC 7MW4911
November 26, 2025
·
4 min read
Press Releases
Mabwell Receives IND Clearance for Novel Anti-ST2 Monoclonal Antibody 9MW1911 to Initiate Phase IIa Study
December 25, 2025
·
4 min read
Press Releases
Mabwell’s CDH17-targeting ADC 7MW4911 Receives IND Clearance from NMPA
October 15, 2025
·
5 min read
Press Releases
Mabwell’s Novel Anti‑IL‑11 Monoclonal Antibody 9MW3811 Approved by NMPA to Initiate Phase II Clinical Trial in Pathological Scarring
November 11, 2025
·
5 min read
Press Releases
Annualized Severe COPD Exacerbation Rate Reduced by Over 40%: Mabwell Announces Phase IIa Results for Innovative Anti-ST2 Antibody 9MW1911
December 2, 2025
·
5 min read
Press Releases
Mabwell Bioscience and Aditum Bio Announce Formation of Kalexo Bio to Advance Innovative siRNA Therapy for Cardiovascular Disorders
September 18, 2025
·
3 min read
Press Releases
Mabwell’s CDH17-targeting ADC 7MW4911 Receives IND Clearance from FDA
August 20, 2025
·
5 min read
Press Releases
enGene Announces Name Change to enGene Therapeutics Inc.
April 7, 2026
·
8 min read
1 of 74,372
Next
